Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kalos

Showing results (181-190 of 236) with videos related to

Pageof 24
Sort By:
Psychiatric Services (Washington, D.C.)|June 2, 2017
Perceived Autonomy Support in the NIMH RAISE Early Treatment ProgramJulia Browne, David L Penn, Daniel J Bauer, et al.
The American Journal of Pathology|January 10, 2014
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytesQian Zhang, Fang Wei, Hong Yi Wang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
Psychiatric Services (Washington, D.C.)|January 5, 2016
Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of CareMary F Brunette, Armando J Rotondi, Dror Ben-Zeev, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
The Cancer Journal From Scientific American|June 10, 1998
Genetic modification of T-cell clones for therapy of human viral and malignant diseasesP D Greenberg, R J Finch, M A Gavin, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Eclinicalmedicine|January 26, 2024
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysisMahati Paravathaneni, Houssein Safa, Vidhu Joshi, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Blood|May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyDavid T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Pageof 24

Showing results (181-190 of 236) with videos related to

Sort By:
Pageof 24
Psychiatric Services (Washington, D.C.)|June 2, 2017
Perceived Autonomy Support in the NIMH RAISE Early Treatment ProgramJulia Browne, David L Penn, Daniel J Bauer, et al.
The American Journal of Pathology|January 10, 2014
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytesQian Zhang, Fang Wei, Hong Yi Wang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
Psychiatric Services (Washington, D.C.)|January 5, 2016
Coordinated Technology-Delivered Treatment to Prevent Rehospitalization in Schizophrenia: A Novel Model of CareMary F Brunette, Armando J Rotondi, Dror Ben-Zeev, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
The Cancer Journal From Scientific American|June 10, 1998
Genetic modification of T-cell clones for therapy of human viral and malignant diseasesP D Greenberg, R J Finch, M A Gavin, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Eclinicalmedicine|January 26, 2024
15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysisMahati Paravathaneni, Houssein Safa, Vidhu Joshi, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Blood|May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyDavid T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Pageof 24